Rodrigo Suarez-Ibarrola1, Arkadiusz Miernik2, Christian Gratzke2, Dominik S Schoeb2. 1. Department of Urology, Faculty of Medicine, University of Freiburg-Medical Centre, Freiburg, Germany. rodrigo.suarez@uniklinik-freiburg.de. 2. Department of Urology, Faculty of Medicine, University of Freiburg-Medical Centre, Freiburg, Germany.
Abstract
PURPOSE: To review and discuss the literature regarding iTIND, Urolift and Rezūm and investigate the precise clinical indications of all three different approaches for their application in benign prostatic hyperplasia (BPH) treatment. MATERIALS AND METHODS: The PubMed-Medline and Cochrane Library databases were screened to identify recent English literature relevant to iTIND, Urolift and Rezūm therapies. The surgical technique and clinical results for each approach were summarized narratively. RESULTS: iTIND, Urolift and Rezūm are safe and effective minimally invasive procedures for the symptomatic relief of lower urinary tract symptoms (LUTS) due to BPH. iTIND requires the results of ongoing prospective studies, a long-term follow-up and a comparison against a reference technique to confirm the generalizability of the first pivotal study. Urolift provides symptomatic relief but the improvements are inferior to TURP at 24 months and long-term retreatments have not been evaluated. Rezūm requires randomized controlled trials against a reference technique to confirm the first promising clinical results. However, clinical evidence from prospective clinical trials demonstrates the efficacy and safety of these procedures in patients with small- and medium-sized prostates. CONCLUSIONS: Although iTIND, Urolift, and Rezūm cannot be applied to all bladder outlet obstruction (BOO) cases resulting from BPH, they provide a safe alternative for carefully selected patients who desire symptom relief and preservation of erectile and ejaculatory function without the potential morbidity of more invasive procedures.
PURPOSE: To review and discuss the literature regarding iTIND, Urolift and Rezūm and investigate the precise clinical indications of all three different approaches for their application in benign prostatic hyperplasia (BPH) treatment. MATERIALS AND METHODS: The PubMed-Medline and Cochrane Library databases were screened to identify recent English literature relevant to iTIND, Urolift and Rezūm therapies. The surgical technique and clinical results for each approach were summarized narratively. RESULTS:iTIND, Urolift and Rezūm are safe and effective minimally invasive procedures for the symptomatic relief of lower urinary tract symptoms (LUTS) due to BPH. iTIND requires the results of ongoing prospective studies, a long-term follow-up and a comparison against a reference technique to confirm the generalizability of the first pivotal study. Urolift provides symptomatic relief but the improvements are inferior to TURP at 24 months and long-term retreatments have not been evaluated. Rezūm requires randomized controlled trials against a reference technique to confirm the first promising clinical results. However, clinical evidence from prospective clinical trials demonstrates the efficacy and safety of these procedures in patients with small- and medium-sized prostates. CONCLUSIONS: Although iTIND, Urolift, and Rezūm cannot be applied to all bladder outlet obstruction (BOO) cases resulting from BPH, they provide a safe alternative for carefully selected patients who desire symptom relief and preservation of erectile and ejaculatory function without the potential morbidity of more invasive procedures.
Keywords:
(MeSH terms of the US national library of medicine); Benign prostatic hyperplasia; Bladder outlet obstruction; Male urologic surgical procedures; Minimal invasive surgical procedures; Urinary tract disease
Authors: Jens Sønksen; Neil J Barber; Mark J Speakman; Richard Berges; Ulrich Wetterauer; Damien Greene; Karl-Dietrich Sievert; Christopher R Chapple; Francesco Montorsi; Jacob M Patterson; Lasse Fahrenkrug; Martin Schoenthaler; Christian Gratzke Journal: Eur Urol Date: 2015-04-30 Impact factor: 20.096
Authors: Claus G Roehrborn; Daniel B Rukstalis; Jack Barkin; Steven N Gange; Neal D Shore; Jonathan L Giddens; Damien M Bolton; Barrett E Cowan; Anthony L Cantwell; Kevin T McVary; Alexis E Te; Shahram S Gholami; William G Moseley; Peter T Chin; William T Dowling; Sheldon J Freedman; Peter F Incze; K Scott Coffield; Fernando D Borges; Prem Rashid Journal: Can J Urol Date: 2015-06 Impact factor: 1.344
Authors: Peter T Chin; Damien M Bolton; Greg Jack; Prem Rashid; Jeffrey Thavaseelan; R James Yu; Claus G Roehrborn; Henry H Woo Journal: Urology Date: 2012-01 Impact factor: 2.649
Authors: Christian Gratzke; Neil Barber; Mark J Speakman; Richard Berges; Ulrich Wetterauer; Damien Greene; Karl-Dietrich Sievert; Christopher R Chapple; Jacob M Patterson; Lasse Fahrenkrug; Martin Schoenthaler; Jens Sonksen Journal: BJU Int Date: 2016-12-21 Impact factor: 5.588
Authors: Claus G Roehrborn; Jack Barkin; Steven N Gange; Neal D Shore; Jonathan L Giddens; Damien M Bolton; Barrett E Cowan; Anthony L Cantwell; Kevin T McVary; Alexis E Te; Shahram S Gholami; William G Moseley; Peter T Chin; William T Dowling; Sheldon J Freedman; Peter F Incze; K Scott Coffield; Sean Herron; Prem Rashid; Daniel B Rukstalis Journal: Can J Urol Date: 2017-06 Impact factor: 1.344
Authors: Daniel Rukstalis; Prem Rashid; William K Bogache; Ronald F Tutrone; Jack Barkin; Peter T Chin; Henry H Woo; Anthony L Cantwell; Barrett E Cowan; Damien M Bolton Journal: BJU Int Date: 2016-10 Impact factor: 5.588